Photo by fusion_medical_animation from unsplash
Early‐stage and intermediate‐stage nasopharyngeal cancer (NPC) generally carry a good prognosis, but for patients with recurrent, metastatic disease, options are limited. In the current study, the authors present a phase… Click to show full abstract
Early‐stage and intermediate‐stage nasopharyngeal cancer (NPC) generally carry a good prognosis, but for patients with recurrent, metastatic disease, options are limited. In the current study, the authors present a phase 1/2 study to evaluate the efficacy of Epstein‐Barr virus (EBV)‐stimulated cytotoxic T‐lymphocyte (EBV‐CTL) immunotherapy in this patient population.
Keywords:
barr virus;
recurrent metastatic;
epstein barr;
immunotherapy
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!